Therapeutic agent

Ivabradine

ModerateEvidence level
2Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Enrollment: Actual, Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Fed
Safety
Bradycardia, visual phosphenes (luminous phenomena), headache. Contraindicated in sick sinus, severe hypotension, acute decompensated HF. Monitor HR.
Dosing
2.5–7.5 mg twice daily; titrate to HR; durations in POTS/autonomic studies 4–12 weeks or longer.
Observational success ~55% + nested COVIVA RCT. Selective HR reduction without beta effects. 2.5-7.5mg BID. Visual side effects possible. Strong for hyperadrenergic POTS/IST phenotypes.

Clinical Trials

2 trial(s) registered

NCT IDTitlePhaseStatus
NCT06305806RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)Phase 2Completed
NCT05481177Ivabradine for Long-Term Effects of COVID-19 With POTS CohortPhase 4Unknown status

Key Studies / References

  • See linked studies